Antibodies in immune-mediated peripheral neuropathies. Where are we in 2024?

Rev Neurol (Paris). 2024 Nov;180(9):876-887. doi: 10.1016/j.neurol.2024.09.002. Epub 2024 Sep 24.

Abstract

Over the past 30 years, about 20 antibodies have been identified in immune-mediated neuropathies, recognizing membrane or intracellular proteins or glycolipids of neuron and Schwann cells. This article reviews the different methods used for their detection, what we know about their pathogenic role, how they have helped identify several disorders, and how they are essential for diagnosis. Despite sustained efforts, some immune-mediated disorders still lack identified autoantibodies, notably the classical form of Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. The reasons for this are discussed. The article also tries to determine potential future developments in antibody research, particularly the use of omic approaches and the search for other types of biomarkers beyond diagnostic ones, such as those that can identify patients who will respond to a given treatment.

Keywords: Antiganglioside antibodies; CIDP; Nodopathies; Protein array; Sensory neuronopathy; Small fiber neuropathy.

Publication types

  • Review

MeSH terms

  • Autoantibodies* / blood
  • Autoantibodies* / immunology
  • Biomarkers / blood
  • Guillain-Barre Syndrome / diagnosis
  • Guillain-Barre Syndrome / immunology
  • Humans
  • Peripheral Nervous System Diseases* / diagnosis
  • Peripheral Nervous System Diseases* / immunology
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / diagnosis
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / immunology

Substances

  • Autoantibodies
  • Biomarkers